- Home
- GOOD vs RIGL Comparison
GOOD vs RIGL Comparison
Compare GOOD & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOOD
- RIGL
- Stock Information
- Founded
- GOOD 2003
- RIGL 1996
- Country
- GOOD United States
- RIGL United States
- Employees
- GOOD N/A
- RIGL N/A
- Industry
- GOOD Real Estate Investment Trusts
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- GOOD Real Estate
- RIGL Health Care
- Exchange
- GOOD Nasdaq
- RIGL Nasdaq
- Market Cap
- GOOD 534.5M
- RIGL 537.6M
- IPO Year
- GOOD N/A
- RIGL 2000
- Fundamental
- Price
- GOOD $11.21
- RIGL $39.38
- Analyst Decision
- GOOD
- RIGL Buy
- Analyst Count
- GOOD 0
- RIGL 6
- Target Price
- GOOD N/A
- RIGL $39.83
- AVG Volume (30 Days)
- GOOD 621.2K
- RIGL 630.3K
- Earning Date
- GOOD 11-03-2025
- RIGL 11-04-2025
- Dividend Yield
- GOOD 10.68%
- RIGL N/A
- EPS Growth
- GOOD N/A
- RIGL 2698.26
- EPS
- GOOD 0.18
- RIGL 6.20
- Revenue
- GOOD $155,250,000.00
- RIGL $282,076,000.00
- Revenue This Year
- GOOD $7.79
- RIGL $59.93
- Revenue Next Year
- GOOD $5.12
- RIGL N/A
- P/E Ratio
- GOOD $61.32
- RIGL $6.45
- Revenue Growth
- GOOD 4.95
- RIGL 79.13
- 52 Week Low
- GOOD $10.58
- RIGL $14.63
- 52 Week High
- GOOD $17.88
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- GOOD 44.88
- RIGL 67.14
- Support Level
- GOOD $10.58
- RIGL $34.00
- Resistance Level
- GOOD $11.45
- RIGL $39.56
- Average True Range (ATR)
- GOOD 0.28
- RIGL 2.16
- MACD
- GOOD 0.04
- RIGL 1.00
- Stochastic Oscillator
- GOOD 67.02
- RIGL 94.32
About GOOD Gladstone Commercial Corporation Real Estate Investment Trust
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.